

# Ahmed O Shalash

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9009583/ahmed-o-shalash-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14  
papers

108  
citations

7  
h-index

10  
g-index

18  
ext. papers

182  
ext. citations

6  
avg, IF

3.2  
L-index

#	Paper	IF	Citations
14	Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2015</b> , 96, 291-303	5.7	17
13	A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed. <i>AAPS PharmSciTech</i> , <b>2017</b> , 18, 2862-2870	3.9	16
12	Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	13
11	Poly(hydrophobic amino acid)-Based Self-Adjuvanting Nanoparticles for Group A Vaccine Delivery. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 2648-2658	8.3	13
10	The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance. <i>AAPS PharmSciTech</i> , <b>2018</b> , 19, 912-922	3.9	12
9	Modeling the performance of carrier-based dry powder inhalation formulations: Where are we, and how to get there?. <i>Journal of Controlled Release</i> , <b>2018</b> , 279, 251-261	11.7	10
8	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <i>Advanced Science</i> , <b>2021</b> , 8, e2100985	13.6	8
7	Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. <i>Clinical and Translational Immunology</i> , <b>2021</b> , 10, e1260	6.8	7
6	Oral Peptide Vaccine against Hookworm Infection: Correlation of Antibody Titers with Protective Efficacy. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	4
5	Cyclic Dipeptides: The Biological and Structural Landscape with Special Focus on the Anti-Cancer Proline-Based Scaffold. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	3
4	Hookworm infection: Toward development of safe and effective peptide vaccines. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 1394-1419.e6	11.5	1
3	Detection and Quantification of SARS-CoV-2 Receptor Binding Domain Neutralization by a Sensitive Competitive ELISA Assay.. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	1
2	Insights into the potential of rheological measurements in development of dry powder inhalation formulations.. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 121407	6.5	0
1	Investigation of liposomal self-adjuvanting peptide epitopes derived from conserved blood-stage Plasmodium antigens.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264961	3.7	